Evidence map›Paper›PMID 40271874›Full record

ArticleMaterials (Basel, Switzerland)2025

Investigation of 2-Mercapto-1-Methylimidazole as a New Type of Leveler in Wafer Electroplating Copper.

Tong Tan, Renlong Liu, Lanfeng Guo, Zhaobo He, Xing Fan, Rui Ye, Changyuan Tao

Abstract read
In one paragraph

Article in Materials (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tong TanSchool of Chemistry and Chemical Engineering, Chongqing University, Chongqing 400044, China.
Renlong LiuSchool of Chemistry and Chemical Engineering, Chongqing University, Chongqing 400044, China.ORCID 0009-0004-3716-2123
Lanfeng GuoSchool of Chemistry and Chemical Engineering, Chongqing University, Chongqing 400044, China.
Zhaobo HeHubei Sinophorus Electronic Materials Co., Ltd., Yichang 443007, China.
Xing FanSchool of Chemistry and Chemical Engineering, Chongqing University, Chongqing 400044, China.ORCID 0000-0002-8663-2599
Rui YeHubei Sinophorus Electronic Materials Co., Ltd., Yichang 443007, China.
Changyuan TaoSchool of Chemistry and Chemical Engineering, Chongqing University, Chongqing 400044, China.

Funding

Hubei Sinophorus Electronic Materials Co. H20230428
6 · The paper itself

Abstract

Through-Silicon-Via (TSV) technology is of crucial importance in the process of defect-free copper filling in vias. In this study, the small molecule 2-mercapto-1-methylimidazole (SN2) is proposed as a new leveler. It enables bottom-up super-filling of blind vias without the need for inhibitors. Atomic force microscopy (AFM), X-ray diffraction (XRD), and XPS were employed to characterize the surface morphology, crystal structure, and adsorption properties of copper crystals in these systems. Meanwhile, by means of electrochemical measurements, the inhibitory effect of the leveler SN2 on copper ion deposition and the synergistic effect between SN2 molecules and other additives were investigated. The LSV test indicated that additive SN2 inhibited copper electrodeposition after being added to the plating solution, and this inhibitory effect enhanced with increasing SN2 concentration. In the actual plating wafer test (1 ASD plating for 1 min, 5 ASD plating for 5 min, and 10 ASD plating for 1 h), the best plating effect was achieved at 3 ppm, which verified the conjecture of the galvanostatic measurements. Moreover, XPS and computer simulations revealed that SN2 could be adsorbed onto the copper surfaces. This work will inspire the discovery of new effective levelers in the future.

Indexed as

chip copper interconnectionlevelerwafer plating

Identifiers

PMID40271874
PMCPMC11990726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.